Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

A#2651 Vasculitis w VEXAS 81 men, median age 67 - 27% had evid of vasculitis, variable size vessel 22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx 2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+ @RheumNow #ACR24 https://t.co/puablIBLCP

Subsets of lupus arthritis. Kenneth Kalunian @RheumNow #ACR24 https://t.co/ZmHui126zr

Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

How often do you ask about #fatigue, #depression & #anxiety in pts with RMDs? Study of >1000 pts found anxiety symptoms in 1/3 pts and significant association between fatigue & anxiety and depression Highlights importance of regular review of MH symptoms Ab2657 #ACR24 @RheumNow https://t.co/0zMOMybrCI

A#2652 NEWTON study 🇫🇷 Retrosp cohort 51% relapse. Median @8.7 mos, dose 9mg pred Rf: limb art involv- HR 1.9 Pred taper speed not risk for relapse Most relapse -> incr GCs Toci 1/3 at dx, 50% stopped -61% d/c due to remission, 39% SEs -1/3 relapse after d/c @RheumNow #ACR24 https://t.co/NP0wieDmvo

Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww

A New ACR Dr. Jack Cush highlights a few notable changes to the ACR meeting format this year, and offers pointers on the best way to stay informed and abreast of reporting from the #ACR24 Convergence meeting in Washington, DC. https://t.co/YmI6s1TanV https://t.co/hsByGEBtnz

A#2648 PET for GCA Delayed imaging at 180 min improve dx performance for pts on GCs Optimal PET w/in 3 days of GC, most patients unable to do w/in that window Delay has sensitivity 92% even on prednisone - may be good tool for pts unable to get early PET/CT #ACR24 @RheumNow https://t.co/kxpNfRqkGN

Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis. - Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension. - 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb